Controlled Human Malaria Infection Transmission Model - Phase A (CHMI-TransMod)

Recruitment & Eligibility

Status: Pending

Sex: All

Target Recruitment: 44

Inclusion Criteria

•Healthy adults aged 18 to 45 years.
•Able and willing (in the Investigator’s opinion) to comply with all study requirements.
•Informed consent.
•Use of effective method of contraception for duration of study (women only). We will ask the female volunteers to come with their family planning records to verify. Effective contraception is defined as a contraceptive method with failure rate of less than 1% per year when used consistently and correctly, in accordance with the product label. Examples of these include: combined oral contraceptives; injectable progestogen; implants of etenogestrel or levonorgestrel; intrauterine device or intrauterine system; male partner sterilisation at least 6 months prior to the female subject’s entry into the study, and the relationship is monogamous; male condom combined with a vaginal spermicide (foam, gel, film, cream or suppository); and male condom combined with a female diaphragm, either with or without a vaginal spermicide (foam, gel, film, cream, or suppository).

Exclusion Criteria

•Body weight of less than 50kg or body mass index (BMI) less than 18 or greater than 25 kg/m2 at screening.
•Use of systemic antibiotics with known antimalarial activity within 30 days of administration of PfSPZ Challenge (e.g. trimethoprim-sulfamethoxazole, doxycycline, tetracycline, clindamycin, erythromycin, fluoroquinolones and azithromycin).
•Receipt of an investigational product in the 30 days preceding enrolment, or planned receipt during the study period.
•Current participation in another clinical trial or recent participation within 12 weeks of enrolment.
•Prior receipt of an investigational malaria vaccine.
•Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV infection; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 6 months (inhaled and topical steroids are allowed). This will also include Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) positivity.
•Use of immunoglobulins or blood products within 3 months prior to enrolment.

•Any serious medical condition reported or identified during screening that increases the risk of CHMI.
•Any clinically significant abnormal finding on biochemistry or haematology blood tests, urinalysis or clinical examination.
•Women only; pregnancy, or an intention to become pregnant during the duration of the study.
•Sickle cell trait or disease.
•History of drug or alcohol abuse.
•Known hypersensitivity to or contraindications for use of artemether-lumefantrine, chloroquine, piperaquine, primaquine, sulfadoxine-pyrimethamine, or history of severe (allergic) reactions to mosquito bites.
•Confirmed gametocyte positivity at screening and/or a day before challenge
•Confirmed parasite positive by PCR a day before challenge i.e. at C-1.

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Safety and optimisation of sporozoite dose for infections success in individuals with moderate-high malaria exposure [ Time Frame: Up to 42 days post infection with PfSPZ challenge ]<br>Magnitude and frequency of adverse events in the study groups<br><br>Prevalence of gametocytes [ Time Frame: Up to 42 days post infection with PfSPZ challenge ]<br>Prevalence of gametocytes as determined by qRT-PCR

Secondary Outcome Measures

Name	Time	Method
se of sub-curative anti-malaria treatment for induction of gametocytes [ Time Frame: Up to 42 days post infection with PfSPZ challenge ]<br>Density of gametocytes as measured by qRT-PCR<br><br>Peak density and time point of gametocytaemia [ Time Frame: Up to 42 days post infection with PfSPZ challenge ]<br>Peak density and peak time point of gametocytes by drug-regimen and determine the area under the curve of density over time

Related Trials